XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer.
XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer.
复制标题
XRCC3 Thr241Met 与晚期非小细胞肺癌对铂类化疗的反应相关，但与生存无关。
DOI：
10.1371/journal.pone.0077005
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Yin R
中科院分区：
文献类型：
--
作者：
Qiu M;Xu L;Yang X;Ding X;Hu J;Jiang F;Xu L;Yin R
已有大量研究探讨了XRCC3基因Thr241Met多态与非小细胞癌(NSCLC)临床预后的关系，但结论仍有争议。我们进行了这项荟萃分析，以评估XRCC3Thr241Met基因多态性对非小细胞肺癌患者疗效和总生存期的预测价值。合并优势比(OR)和风险比(HR)以及相应的95%可信区间(95%CI)被用来估计关联强度。根据我们的纳入标准，总共确定了14项符合条件的研究，2828名患者。Meta分析结果显示，携带241Met变异等位基因的患者与携带野生241Thr等位基因的患者有显著相关性(Met vs.Thr，OR = 1.453，95%CI：1.116-1.892；P异质性 = 0.968和ThrMet+甲硫氨酸vs.ThrThr，OR = 1.476，95%CI：1.087-2.004；P异质性 = ：0.696)。这种显著的相关性在高加索人群中被观察到，但在亚洲人群中没有。另一方面，XRCC3Thr241Met多态与存活率无显著关联(ThrMet+Met vs.ThrThr，HR = 1.082，95%CI：0.929-1.261，P异质性 = 0.564)，亚洲和高加索人群之间也没有差异。这些发现提示XRCC3Thr241Met基因多态对晚期非小细胞肺癌患者铂类药物化疗的疗效有预测作用。此外，我们首次报道了XRCC3Thr241Met多态与铂类化疗的疗效相关，并强调了XRCC3Thr241Met多态对预后的价值。
A lot of studies have investigated the correlation between x-ray repair cross-complementing group 3 (XRCC3) Thr241Met polymorphism and clinical outcomes in non-small cell cancer (NSCLC), while the conclusion is still conflicting. We conducted this meta-analysis to evaluate the predictive value of XRCC3 Thr241Met polymorphism on response and overall survival of patients with NSCLC. Pooled odds ratios (ORs) and hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) were used to estimate the association strength. A total of 14 eligible studies with 2828 patients were identified according to our inclusion criteria. Meta-analysis results showed that carriers of the variant 241Met allele were significantly associated with good response, compared with those harboring the wild 241Thr allele (Met vs. Thr, OR = 1.453, 95% CI: 1.116–1.892, Pheterogeneity = 0.968 and ThrMet+MetMet vs. ThrThr, OR = 1.476, 95% CI: 1.087–2.004, Pheterogeneity = 0.696). This significant association was observed in Caucasian population but not in Asian population. On the other hand, there was no significant association of XRCC3 Thr241Met polymorphism with survival (ThrMet+MetMet vs. ThrThr, HR = 1.082, 95% CI: 0.929–1.261, Pheterogeneity = 0.564), and there was no difference between Asian and Caucasian population. These findings suggest a predictive role of XRCC3 Thr241Met polymorphism on response to platinum-based chemotherapy in patients with advanced NSCLC. Additionally, we first report that the XRCC3 Thr241Met polymorphism is associated with response to platinum-based chemotherapy and highlights the prognostic value of the XRCC3 Thr241Met polymorphism.
登录
查看更多内容
影响因子：
2.5
作者：
Tierney JF;Stewart LA;Ghersi D;Burdett S;Sydes MR
通讯作者：
Sydes MR
影响因子：
15.8
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
影响因子：
--
作者：
Ke, Hong-Gang;Li, Jun;Shen, Zhen-Ya
通讯作者：
Shen, Zhen-Ya
影响因子：
3
作者：
Provencio, M.;Camps, C.;Rosell, R.
通讯作者：
Rosell, R.
影响因子：
7
作者：
Cohn, LD;Becker, BJ
通讯作者：
Becker, BJ